Patents Assigned to Academisch Ziekenhuis Leiden
-
Patent number: 11174224Abstract: This invention relates to compounds that are useful as inhibitors, in particular as inhibitors of Cathepsin K (CatK), and to a method of inhibiting cathepsin activity, comprising administering a compound or formulation comprising a compound according to the invention.Type: GrantFiled: December 5, 2018Date of Patent: November 16, 2021Assignee: ACADEMISCH ZIEKENHUIS LEIDEN (H.O.D.N. LUMC)Inventors: Huib Ovaa, Maria Wilhelmina Elisabeth Mons, Stan Van Boeckel
-
Patent number: 11077131Abstract: The disclosure is based on the finding that compounds capable of binding to (or interacting with) chromatin binding/remodelling complexes (for example Polycomb group PRC1 and Trithorax group MLL) and/or modulation of the same can be used to modulate (for example switch on/off) ciliogenesis as may occur, for example, in the human pulmonary bronchial epithelium. Provided are compounds, compositions, methods and medicaments which may be used to treat and/or prevent diseases and/or conditions associated with aberrant or defective ciliogenesis.Type: GrantFiled: November 17, 2016Date of Patent: August 3, 2021Assignee: Academisch Ziekenhuis Leiden a/u Leiden University Medical CenterInventor: Ronald Karel Louisa Van Brempt
-
Patent number: 10975441Abstract: The present invention stems from the finding that two genes designated R2R1 and R2R2, play important roles in tissue development and cancer biology. In particular, the inventors have discovered that these two genes are expressed in pulmonary cells and are required for late branching morphogenesis of pulmonary epithelium and endothelium and support the development/maintenance of the refined three dimensional architecture of the lung. These genes are essential in the squamous differentiation program and development/maintenance of the progenitor (Krt14 expressing) cell pool. Moreover, the inventors have identified crucial roles for these genes in cancer biology, particularly processes associated with the acquisition of an immortal and metastatic phenotype (including cancer progression and metastasis) and pulmonary and cardiac development. Accordingly, the invention provides compounds and methods for use in the treatment of cardiac and pulmonary diseases and well as in cancer.Type: GrantFiled: December 19, 2016Date of Patent: April 13, 2021Assignees: Academisch Ziekenhuis Leiden A/U Leiden Uni Medical Ctr, Janssen Pharmaceutica NVInventors: Jeroen Marcel Maria Roger Aerssens, Ronald Karel Louisa Van Brempt, Pieter Johan Peeters, Ronald Anthonius de Hoogt, Marcus Cornelis de Ruiter
-
Publication number: 20210085809Abstract: The present invention relates to a vaccine composition for use in in vivo administration, comprising a (attenuated) pathogen or commensal modified to be a pre-targeting vector, the pre-targeting vector comprising one or more pendent reactive moieties able to form a high affinity interaction with a complementary moiety residing on an immunogenic conjugate component.Type: ApplicationFiled: July 27, 2018Publication date: March 25, 2021Applicant: ACADEMISCH ZIEKENHUIS LEIDEN (h.o.d.n. LUMC)Inventors: Fijs W. B. VAN LEEUWEN, Meta ROESTENBERG
-
Patent number: 10933163Abstract: The present disclosure relates to in situ tissue engineering, more specifically in situ vascular tissue engineering with the aim of providing a tissue structure which can be used e.g. as a substitute blood vessel or as a blood vessel functioning as cannulation site in hemodialysis. In particular, the disclosure involves tissue structure formation around a subcutaneously implanted synthetic rod. In addition, the disclosure involves a method for producing said synthetic rod.Type: GrantFiled: January 31, 2019Date of Patent: March 2, 2021Assignees: Academisch Ziekenhuis Leiden, Xeltis B.V., Universiteit MaastrichtInventors: Joris Ivo Rotmans, Tonia Caroline Rothuizen, Lorenzo Moroni, Clemens Antoni Van Blitterswijk, Febriyani Fiain Rochel Damanik, Tom Lavrijsen, Martijn Antonius Johannes Cox, Antonius Johannes Rabelink
-
Patent number: 10876114Abstract: The invention relates a method wherein a molecule is used for inducing and/or promoting skipping of at least one of exon 43, exon 46, exons 50-53 of the DMD pre-mRNA in a patient, preferably in an isolated cell of a patient, the method comprising providing the cell and/or the patient with a molecule. The invention also relates to the molecule as such.Type: GrantFiled: June 29, 2018Date of Patent: December 29, 2020Assignees: BioMarin Technologies B.V., Academisch Ziekenhuis LeidenInventor: Judith Christina Theodora Van Deutekom
-
Publication number: 20200385341Abstract: This invention relates to compounds that are useful as inhibitors, in particular as inhibitors of Cathepsin K (CatK), and to a method of inhibiting cathepsin activity, comprising administering a compound or formulation comprising a compound according to the invention.Type: ApplicationFiled: December 5, 2018Publication date: December 10, 2020Applicant: ACADEMISCH ZIEKENHUIS LEIDEN (H.O.D.N. LUMC)Inventors: Huib OVAA, Maria Wilhelmina Elisabeth MONS, Stan VAN BOECKEL
-
Publication number: 20200378968Abstract: The present invention relates to a method for labeling or targeting cells whose plasma membrane has lost integrity, such as dead cells, such as for discriminating between live cells and cells whose plasma membrane has lost integrity; to an embodiment of the method for determining one or more values of one or more parameters of cells of a biological sample; to use of the method in an assay for screening drugs for therapy such as cancer therapy; to use of the method to monitor and/or determine the effectiveness of a therapy; to an assay kit; to a complex; to the complex for use as a medicament; to the complex for use in treatment of cancer(s) and/or plaque(s) and/or regeneration and/or supporting the immune system; and, to a dead cell.Type: ApplicationFiled: April 10, 2020Publication date: December 3, 2020Applicants: HQ Medical Netherlands B.V., Publiekrechtelijk rechtspersoon Academisch Ziekenhuis Leiden h.o.d.n. LUMCInventors: Markwin Hendrik Maring, Clemens Waltherus Gerardus Löwik, Ermond Reijer Van Beek
-
Publication number: 20200289640Abstract: The present invention relates to novel CD4+ and CD8+ T cell epitopes that are specific for HPV-specific E6 and E7 oncoproteins, to peptides comprising these novel T cell epitopes, and to (vaccine) compositions comprising these peptides for use in methods for the prevention and/or treatment of HPV related diseases. Preferred epitopes are recognized by a T cell that infiltrates a cervical neoplastic lesion or by a T cell from a draining lymph node, and are presented by an HLA-DQ or HLA-DP molecule, or an HLA-B.Type: ApplicationFiled: May 27, 2020Publication date: September 17, 2020Applicant: Academisch Ziekenhuis Leiden H.O.D.N. LUMCInventors: Sjoerd Henricus Van Der Burg, Gemma G. Kenter, Cornelis Johannes Maria Melief
-
Publication number: 20200276441Abstract: The present invention relates to a system, its catheter and its method for providing electrical pulses and/or therapeutic or diagnostic liquids directly to a pituitary gland of a mammal. The catheter, containing an electrode or a microcannula or both, is moved through an endovascular route of a patient to his/her sinus cavernosus and then the distal end of the electrode or microcannula is moved through an opening in the distal end of the catheter and then through a perforation in the medial wall of the sinus cavernosus, to the pituitary gland.Type: ApplicationFiled: November 14, 2018Publication date: September 3, 2020Applicant: ACADEMISCH ZIEKENHUIS LEIDEN (H.O.D.N. LUMC)Inventors: Wouter R. VAN FURTH, Nienke R.. BIERMASZ, Amir H. ZAMANIPOOR NAJAFABADI
-
Patent number: 10746745Abstract: The present invention relates to the identification of chemokine biomarkers predictive of future acute coronary syndromes including unstable angina pectoris (UAP). The present invention also identifies particular chemokines as potential therapeutic targets for intervention in cardiovascular diseases.Type: GrantFiled: January 11, 2018Date of Patent: August 18, 2020Assignees: Academisch Ziekenhuis Leiden, Universiteit LeidenInventors: Ericus Anna Leonardus Biessen, Theodorus Josephus Cornelis Van Berkel, Adriaan Otto Kraaijeveld
-
Patent number: 10688173Abstract: The present invention relates to novel CD4+ and CD8+ T cell epitopes that are specific for HPV-specific E6 and E7 oncoproteins, to peptides comprising these novel T cell epitopes, and to (vaccine) compositions comprising these peptides for use in methods for the prevention and/or treatment of HPV related diseases. Preferred epitopes are recognized by a T cell that infiltrates a cervical neoplastic lesion or by a T cell from a draining lymph node, and are presented by an HLA-DQ or HLA-DP molecule, or an HLA-B.Type: GrantFiled: February 27, 2019Date of Patent: June 23, 2020Assignee: ACADEMISCH ZIEKENHUIS LEIDEN H.O.D.N. LUMCInventors: Sjoerd Henricus Van Der Burg, Gemma G. Kenter, Cornelis Johannes Maria Melief
-
Patent number: 10590421Abstract: Described are methods for removing a proteolytic cleavage site, the HCHWA-D mutation or the amino acids encoded by a trinucleotide repeat expansion from a protein comprising providing a cell that expresses pre-mRNA encoding the protein with an anti-sense oligonucleotide that induces skipping of the exonic sequence that comprises the proteolytic cleavage site, HCHWA-D mutation or trinucleotide repeat expansion, respectively, the method further comprising allowing translation of mRNA produced from the pre-mRNA.Type: GrantFiled: April 21, 2017Date of Patent: March 17, 2020Assignee: Academisch Ziekenhuis Leiden H.O.D.N. LUMCInventors: Wilhelmina M. C. van Roon-Mom, Melvin Maurice Evers, Barry Antonius Pepers, Annemieke Aartsma-Rus, Garrit-Jan Boudewijn Van Ommen
-
Patent number: 10544416Abstract: The invention provides a method for generating an oligonucleotide with which an exon may be skipped in a pre-mRNA and thus excluded from a produced mRNA thereof. Further provided are methods for altering the secondary structure of an mRNA to interfere with splicing processes and uses of the oligonucleotides and methods in the treatment of disease. Further provided are pharmaceutical compositions and methods and means for inducing skipping of several exons in a pre-mRNA.Type: GrantFiled: August 20, 2018Date of Patent: January 28, 2020Assignee: ACADEMISCH ZIEKENHUIS LEIDENInventor: Judith C. Van Deutekom
-
Patent number: 10537618Abstract: This disclosure relates to recombinant FXa polypeptides that can be used as antidotes to completely or partially reverse an anti-coagulant effect of a coagulation inhibitor in a subject, preferably a direct factor Xa inhibitor. Disclosed herein are recombinant factor Xa proteins and a method of completely or partially reversing an anti-coagulant effect of a coagulation inhibitor in a subject.Type: GrantFiled: May 26, 2015Date of Patent: January 21, 2020Assignee: ACADEMISCH ZIEKENHUIS LEIDENInventors: Daniël Verhoef, Pieter H. Reitsma, Mettine H. A. Bos
-
Patent number: 10539563Abstract: Antibodies against citrullinated protein antigens (ACPA) have shown their relevance for the diagnosis and possibly pathogenesis in arthritis. Described are means and methods for determining antibodies against homocitrulline-containing proteins or carbamylated proteins/peptides (anti-CarP) for the classification of individuals suffering from, or at risk of suffering from, arthritis.Type: GrantFiled: September 4, 2018Date of Patent: January 21, 2020Assignee: Academisch Ziekenhuis Leiden H.O.D.N. LUMCInventors: Leendert Adrianus Trouw, Reinaldus Everardus Maria Toes, Thomas Willem Johannes Huizinga, Petrus Antonius van Veelen, Anthony Cerami, Jing Shi
-
Patent number: 10533175Abstract: Disclosed are methods for modulating splicing of Ataxin 3 mRNA in an animal with modified oligonucleotides. Such compounds and methods are useful to treat, prevent, or ameliorate spinocerebellar ataxia type 3 (SCA3) in an individual in need thereof.Type: GrantFiled: September 23, 2016Date of Patent: January 14, 2020Assignees: Ionis Pharmaceuticals, Inc., Academisch Ziekenhuis LeidenInventors: Frank Rigo, Thazha P. Prakash, Wilhelmina Maria Clasina Van Roon-Mom, Lodewijk Julius Anton Toonen
-
Patent number: 10450356Abstract: The invention relates to a peptide having a length of no more than 100 amino acids and comprising at least 19 contiguous amino acids from the amino acid sequence of the human PRAME protein, wherein the peptide comprises at least one HLA class II epitope and at least one HLA class I epitope from the amino acid sequence of the human PRAME protein and to its use as such or in a composition as a medicament for the treatment and/or prevention of cancer.Type: GrantFiled: August 4, 2016Date of Patent: October 22, 2019Assignee: ACADEMISCH ZIEKENHUIS LEIDEN H.O.D.N. LUMCInventors: Jan Kessler, Marieke Griffioen, Cornelis Johannes Maria Melief, Jan Wouter Drijfhout
-
Patent number: 10364432Abstract: The invention relates to means and methods for removing a proteolytic cleavage site from a protein comprising providing a cell that expresses pre-mRNA encoding the protein with an anti-sense oligonucleotide that induces skipping of the exonic sequence that encodes the proteolytic cleavage site, the method further comprising allowing translation of mRNA produced from the pre-mRNA.Type: GrantFiled: February 22, 2017Date of Patent: July 30, 2019Assignee: Academisch Ziekenhuis Leiden h.o.d.n. LUMCInventors: Wilhelmina M. C. van Roon-Mom, Melvin Maurice Evers, Barry Antonius Pepers, Annemieke Aartsma-Rus, Garrit-Jan Boudewijn Van Ommen
-
Patent number: RE48468Abstract: The invention provides means and methods for alleviating one or more symptom(s) of Duchenne Muscular Dystrophy and/or Becker Muscular Dystrophy. Therapies using compounds for providing patients with functional muscle proteins are combined with at least one adjunct compound for reducing inflammation, preferably for reducing muscle tissue inflammation, and/or at least one adjunct compound for improving muscle fiber function, integrity and/or survival.Type: GrantFiled: January 26, 2018Date of Patent: March 16, 2021Assignees: BioMarin Technologies B.V., Academisch Ziekenhuis LeidenInventors: Josephus Johannes De Kimpe, Gerard Johannes Platenburg, Judith Christina Theodora Van Deutekom, Annemieke Aartsma-Rus, Garrit-Jan Boudewijn Van Ommen